Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Sitagliptin phosphate anhydrous formulation
Comparator: sitagliptin phosphate monohydrate form
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Subject is in good health
- Female subjects must have a negative pregnancy test
- Subject is within 30% of ideal body weight
- Subject does not smoke
- Subject agrees to follow the study guidelines
Exclusion Criteria:
- Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject
- Subject has a history of hypoglycemia
- Subject has a history of any hepatic disease
- Subject is taking any oral, parenteral, topical or implantable contraceptives
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1
2
Arm Description
Sitagliptin anhydrous formulation
Sitagliptin monohydrate FMI formulation
Outcomes
Primary Outcome Measures
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00944450
Brief Title
Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
Official Title
An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of Tablet Formulations Containing the Anhydrous and Monohydrate (FMI) Forms of MK0431
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
August 2004 (undefined)
Primary Completion Date
September 2004 (Actual)
Study Completion Date
November 2004 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Sitagliptin anhydrous formulation
Arm Title
2
Arm Type
Active Comparator
Arm Description
Sitagliptin monohydrate FMI formulation
Intervention Type
Drug
Intervention Name(s)
Sitagliptin phosphate anhydrous formulation
Intervention Description
Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
Intervention Type
Drug
Intervention Name(s)
Comparator: sitagliptin phosphate monohydrate form
Intervention Description
Single dose sitagliptin 100 mg tablets [monohydrate Final Market Image (FMI) form] in one of two treatment periods.
Primary Outcome Measure Information:
Title
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Description
Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Time Frame
Through 72 Hours Following the Administration of the Medication
Title
Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Description
Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
Time Frame
Through 72 Hours Following the Administration of the Medication
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subject is in good health
Female subjects must have a negative pregnancy test
Subject is within 30% of ideal body weight
Subject does not smoke
Subject agrees to follow the study guidelines
Exclusion Criteria:
Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject
Subject has a history of hypoglycemia
Subject has a history of any hepatic disease
Subject is taking any oral, parenteral, topical or implantable contraceptives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
We'll reach out to this number within 24 hrs